Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Prevention of Herpes Zoster

Prevention of Herpes Zoster EDITORIAL We Need to Do Better ERPES ZOSTER (HZ) IS A COMMON, SERI- than 70s or 80s; however, reduction in disease burden ous, and preventable disease. Despite the was 66% in all age groups. In a more recent and larger approval of a safe and effective vaccine population-based study, including more patients with in 2006 for immunocompetent pa- chronic diseases, efficacy of 55% was observed in all age H tients aged 60 years or older, underuse groups. In a recent randomized clinical trial, almost 70% 1,2 of this vaccine remains widespread. Understanding the efficacy in disease prevention was observed in patients in barriers to recommended use and implementation of pro- their 50s. Currently, the vaccine is recommended by the grams to overcome them is critically important in de- Centers for Disease Control and Prevention (CDC) for im- creasing this often devastating disease. Somewhat sur- munocompetent patients aged 60 years and older, includ- prisingly, the most important barrier is lack of a strong ing people with a history of HZ and no known history of physician recommendation for this vaccine. We must do chicken pox; it is also Food and Drug Administration– better so that physicians know about zoster and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Prevention of Herpes Zoster

JAMA Ophthalmology , Volume 131 (3) – Mar 1, 2013

Loading next page...
 
/lp/american-medical-association/prevention-of-herpes-zoster-55JtCqMFHH
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2013.588
pmid
23494045
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL We Need to Do Better ERPES ZOSTER (HZ) IS A COMMON, SERI- than 70s or 80s; however, reduction in disease burden ous, and preventable disease. Despite the was 66% in all age groups. In a more recent and larger approval of a safe and effective vaccine population-based study, including more patients with in 2006 for immunocompetent pa- chronic diseases, efficacy of 55% was observed in all age H tients aged 60 years or older, underuse groups. In a recent randomized clinical trial, almost 70% 1,2 of this vaccine remains widespread. Understanding the efficacy in disease prevention was observed in patients in barriers to recommended use and implementation of pro- their 50s. Currently, the vaccine is recommended by the grams to overcome them is critically important in de- Centers for Disease Control and Prevention (CDC) for im- creasing this often devastating disease. Somewhat sur- munocompetent patients aged 60 years and older, includ- prisingly, the most important barrier is lack of a strong ing people with a history of HZ and no known history of physician recommendation for this vaccine. We must do chicken pox; it is also Food and Drug Administration– better so that physicians know about zoster and

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Mar 1, 2013

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month